Stock A180400 DX & VX CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dx & Vx Co., Ltd.

Equities

A180400

KR7180400004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
2,740 KRW -2.14% Intraday chart for Dx & Vx Co., Ltd. -34.61% -53.64%
2023 Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS CI
2023 Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 116,754 171,284 178,619 222,077 222,077 178,592
Enterprise Value (EV) 1 133,039 168,017 179,594 224,699 230,688 205,842
P/E ratio -10.1 x -9.89 x -27.5 x -26 x -285 x -6.36 x
Yield - - - - - -
Capitalization / Revenue 22 x 29.8 x 23.2 x 29.7 x 6.9 x 3.82 x
EV / Revenue 25.1 x 29.2 x 23.3 x 30.1 x 7.17 x 4.4 x
EV / EBITDA -17.8 x -28.2 x -36.2 x -61.4 x 57.6 x -21.3 x
EV / FCF -16.1 x -20.1 x -31.6 x -106 x 67.4 x -460 x
FCF Yield -6.21% -4.96% -3.16% -0.94% 1.48% -0.22%
Price to Book 4.87 x 7.01 x 6.95 x 6.27 x 6.54 x 8.43 x
Nbr of stocks (in thousands) 19,015 22,130 23,077 28,692 28,692 30,219
Reference price 2 6,140 7,740 7,740 7,740 7,740 5,910
Announcement Date 3/20/19 5/14/20 3/12/21 3/22/22 3/15/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5,305 5,753 7,696 7,470 32,184 46,745
EBITDA 1 -7,473 -5,957 -4,968 -3,659 4,006 -9,668
EBIT 1 -7,982 -6,984 -5,979 -4,786 2,634 -12,084
Operating Margin -150.46% -121.39% -77.69% -64.07% 8.18% -25.85%
Earnings before Tax (EBT) 1 -11,259 -18,475 -7,573 -8,023 -2,854 -26,979
Net income 1 -11,348 -17,086 -6,403 -7,269 -779.6 -27,482
Net margin -213.9% -296.98% -83.19% -97.32% -2.42% -58.79%
EPS 2 -607.5 -782.5 -281.0 -298.0 -27.17 -929.2
Free Cash Flow 1 -8,258 -8,340 -5,679 -2,116 3,424 -447
FCF margin -155.66% -144.97% -73.78% -28.33% 10.64% -0.96%
FCF Conversion (EBITDA) - - - - 85.47% -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/20/19 5/14/20 3/12/21 3/22/22 3/15/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 16,285 - 975 2,622 8,610 27,250
Net Cash position 1 - 3,266 - - - -
Leverage (Debt/EBITDA) -2.179 x - -0.1963 x -0.7166 x 2.149 x -2.818 x
Free Cash Flow 1 -8,258 -8,340 -5,679 -2,116 3,424 -447
ROE (net income / shareholders' equity) -41.9% -65.8% -27.3% -27% -4.58% -88.2%
ROA (Net income/ Total Assets) -8.44% -9.57% -12.3% -8.32% 2.59% -8.13%
Assets 1 134,397 178,589 51,972 87,332 -30,118 338,207
Book Value Per Share 2 1,260 1,104 1,114 1,235 1,184 701.0
Cash Flow per Share 2 411.0 124.0 133.0 59.80 881.0 249.0
Capex 1 3,554 2,325 414 942 1,350 760
Capex / Sales 66.99% 40.42% 5.38% 12.61% 4.19% 1.63%
Announcement Date 3/20/19 5/14/20 3/12/21 3/22/22 3/15/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
DX & VX CO., LTD. Stock Dx & Vx Co., Ltd.
-53.64% 59.87M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-38.56% 8.39B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
+0.18% 3.32B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+9.29% 2.49B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-18.21% 2.06B
VERACYTE, INC. Stock Veracyte, Inc.
-24.57% 1.59B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+32.37% 1.15B
SEEGENE, INC. Stock Seegene, Inc.
-7.64% 704M
CAREDX, INC Stock CareDx, Inc
+8.42% 678M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-29.59% 508M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. A180400 Stock
  4. Financials Dx & Vx Co., Ltd.